In addition, USP22 has been shown to inhibit unfolded protein response activity in human epidermal growth factor receptor 2 (HER2)-driven breast cancer (HER2-BC) cells by stabilizing the major endoplasmic reticulum chaperone HSPA5 (105). Here, ERBB2 is linked to breast carcinoma.